Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty

CONTEXT: Gonadotropin-releasing hormone agonists (GnRHas) are standard of care for central precocious puberty (CPP). A 6-month subcutaneous injection has recently been approved by the Food and Drug Administration. OBJECTIVE: Determine efficacy, pharmacokinetics, and safety of 6-month 45-mg subcutane...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Karen O, Freire, Analía, Gryngarten, Mirta Graciela, Kletter, Gad B, Benson, Matthew, Miller, Bradley S, Dajani, Tala S, Eugster, Erica A, Mauras, Nelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442270/
https://www.ncbi.nlm.nih.gov/pubmed/32738042
http://dx.doi.org/10.1210/clinem/dgaa479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442270/
https://www.ncbi.nlm.nih.gov/pubmed/32738042
http://dx.doi.org/10.1210/clinem/dgaa479

Ejemplares similares